SSY Group Limited (02005.HK): Obtains Drug Production Registration Approval for Doxapram Hydrochloride Injection, First Approved in China
NewTimeSpace: SSY Group Limited (02005.HK) announced a voluntary announcement that the Group has obtained the Drug Production Registration Approval for Doxapram Hydrochloride Injection (5ml:100mg) from the National Medical Products Administration (NMPA) of China.The product is classified as a Category 3 chemical drug and is deemed to have passed the consistency evaluation. It is the first approval among domestic enterprises, mainly indicated for the treatment of respiratory failure.
NewTimeSpace : SSY Group Limited (02005.HK) issued a voluntary announcement on March 3, 2026, stating that the Group has obtained the Drug Production Registration Approval for Doxapram Hydrochloride Injection (5ml:100mg) from the NMPA.
The product is a Category 3 chemical drug and is deemed to have passed the consistency evaluation. It is the first product of its kind approved by a domestic enterprise, and is mainly used for the treatment of respiratory failure.
Tags：
- SSY GROUP (02005.HK): Trustee Purchases 1.2 Million Shares on Open Market
- SSY GROUP (02005.HK): Trustee purchases 1,000,000 shares under restricted share award scheme for approximately HKD 2.73 million
- SSY GROUP (02005.HK): Trustee Purchases 900,000 Shares for Approximately HKD 2,414,700 under Restricted Share Award Scheme
- SSY GROUP (02005.HK): Gadobutrol injection and indocyanine green for injection approved, enhancing imaging and critical care product portfolio
- SSY GROUP(02005.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 320.32 million, YoY increase of 12.99%
